Clinical Trial Detail

NCT ID NCT02947165
Title Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

clear cell renal cell carcinoma

triple-receptor negative breast cancer

pancreatic cancer

hepatocellular carcinoma

prostate cancer

Advanced Solid Tumor

colorectal cancer

Therapies

NIS793 + Spartalizumab

NIS793

Age Groups:

Additional content available in CKB BOOST